- Home
- JFBR vs ZVSA Comparison
JFBR vs ZVSA Comparison
Compare JFBR & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFBR
- ZVSA
- Stock Information
- Founded
- JFBR 2017
- ZVSA 2014
- Country
- JFBR Israel
- ZVSA United States
- Employees
- JFBR N/A
- ZVSA N/A
- Industry
- JFBR Other Specialty Stores
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- JFBR Consumer Discretionary
- ZVSA Health Care
- Exchange
- JFBR Nasdaq
- ZVSA Nasdaq
- Market Cap
- JFBR 2.6M
- ZVSA 3.0M
- IPO Year
- JFBR 2022
- ZVSA N/A
- Fundamental
- Price
- JFBR $6.82
- ZVSA $0.69
- Analyst Decision
- JFBR
- ZVSA
- Analyst Count
- JFBR 0
- ZVSA 0
- Target Price
- JFBR N/A
- ZVSA N/A
- AVG Volume (30 Days)
- JFBR 421.4K
- ZVSA 1.5M
- Earning Date
- JFBR 03-31-2025
- ZVSA 08-08-2025
- Dividend Yield
- JFBR N/A
- ZVSA N/A
- EPS Growth
- JFBR N/A
- ZVSA N/A
- EPS
- JFBR N/A
- ZVSA N/A
- Revenue
- JFBR $13,688,000.00
- ZVSA N/A
- Revenue This Year
- JFBR N/A
- ZVSA N/A
- Revenue Next Year
- JFBR N/A
- ZVSA N/A
- P/E Ratio
- JFBR N/A
- ZVSA N/A
- Revenue Growth
- JFBR 36.77
- ZVSA N/A
- 52 Week Low
- JFBR $4.60
- ZVSA $0.47
- 52 Week High
- JFBR $101.33
- ZVSA $6.30
- Technical
- Relative Strength Index (RSI)
- JFBR 49.25
- ZVSA 53.43
- Support Level
- JFBR $6.04
- ZVSA $0.61
- Resistance Level
- JFBR $7.87
- ZVSA $0.73
- Average True Range (ATR)
- JFBR 1.08
- ZVSA 0.07
- MACD
- JFBR 0.41
- ZVSA 0.00
- Stochastic Oscillator
- JFBR 59.91
- ZVSA 36.53
About JFBR Jeffs' Brands Ltd
Jeffs Brands Ltd is an e-commerce CPG company, operating on Amazon. The company serves as the holding company of other e-commerce companies, Smart Repair Pro, Purex, and Top Rank, that operate online stores for the sale of various consumer products on Amazon online marketplace, utilizing the FBA model. The company has five wholly-owned subsidiaries: Smart Repair Pro, Purex, Top Rank, Fort and Jeffs' Brands Holdings. The company also utilizes internal methodologies to analyze sales data and patterns on Amazon to identify existing stores, niches, and products that have the potential for development and growth, and for maximizing sales of existing proprietary products.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.